Medical devices, healthcare technology and the business of care
PMA approval · P210027

QDOT MICRO System

Biosense Webster, Inc. · Decision date Nov 23, 2022

MEDTECHLEDGER EXPLANATIONP210027

What did the FDA approve?

FDA approved the Biosense Webster QDOT MICRO Catheter and related accessory devices on November 23, 2022, under PMA number P210027. The approval covers catheter-based cardiac electrophysiological mapping, including stimulating and recording, and treatment of Type I atrial flutter in patients age 18 or older when used with a compatible RF generator.

The approval also covers drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with compatible three-dimensional electroanatomic mapping systems. The catheter provides real-time contact force measurement between the tip and heart wall, plus location information when used with the CARTO 3 Navigation System. The statement does not include independent proof of safety or clinical effectiveness beyond the approval decision.

FDA approval order statement

Approval for the Biosense Webster QDOT MICRO Catheter and related accessory devices. The device is indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a compatible RF generator, for the treatment of:1) Type I atrial flutter in patients age 18 or older; and2) Drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems. The QDOT MICRO Catheter provides a real-time measurement of contact force between the catheter tip and heart wall, as well as location information when used with CARTO 3 Navigation System.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Nov 23, 2022

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210027
Regulatory pathway
Premarket approval application
Product code
OAE
Decision code
APPR
Decision date
Nov 23, 2022
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210027 received

    Application receipt date recorded by FDA.

  2. P210027 · FDA decision

    APPR

  3. P210027/S019 · Related supplement

    QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER

Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210027

Product / regulatory recordCompanyPathwayDecision dateSource
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA

Explore the linked device profile

Other records with product code OAE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records